Provided by Tiger Fintech (Singapore) Pte. Ltd.

Merck

85.20
+0.49000.58%
Pre-market: 85.05-0.1500-0.18%08:18 EDT
Volume:13.83M
Turnover:1.17B
Market Cap:214.40B
PE:12.39
High:85.83
Open:85.27
Low:83.79
Close:84.71
Loading ...

Germany's Merck KGaA in $3.9 billion deal to buy US biotech firm SpringWorks

Reuters
·
28 Apr

Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

GlobeNewswire
·
28 Apr

Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks

Dow Jones
·
28 Apr

Merck & Co., Inc. (MRK): Among Billionaire Ken Fisher’s Healthcare Stock Picks with Massive Upside Potential

Insider Monkey
·
28 Apr

KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Business Wire
·
28 Apr

2 Outstanding Dividend Stocks to Buy and Hold For 20 Years

Motley Fool
·
27 Apr

Akeso survival data for ivonescimab misses expectations, STAT says

TipRanks
·
27 Apr

Merck First Quarter 2025 Earnings: Beats Expectations

Simply Wall St.
·
26 Apr

Merck’s Earnings Call: Growth Potential and Challenges

TIPRANKS
·
26 Apr

BUZZ-Summit Therapeutics closes 36% lower after interim data for cancer drug

Reuters
·
26 Apr

BMO Capital Adjusts Price Target on Merck to $82 From $89

MT Newswires Live
·
25 Apr

Goldman Sachs Adjusts Merck Price Target to $99 From $103, Maintains Buy Rating

MT Newswires Live
·
25 Apr

ALX Oncology's Phase 2 Trials of Evorpacept, Keytruda Combination in Head, Neck Cancers Fail to Meet Primary Endpoints

MT Newswires Live
·
25 Apr

Dow's 117-Point Drop Led By Losses In Merck, Verizon Shares

Dow Jones
·
25 Apr

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints

GlobeNewswire
·
25 Apr

SpringWorks in Late-Stage Buyout Talks With Merck

MT Newswires Live
·
25 Apr

Citi Remains a Buy on Merck & Company (MRK)

TIPRANKS
·
25 Apr

AbbVie lifts profit forecast, downplays tariff threat

Reuters
·
25 Apr

Morgan Stanley Cuts Price Target on Merck to $99 From $106, Keeps Equalweight Rating

MT Newswires Live
·
25 Apr

AbbVie lifts profit forecast on strong sales of newer immunology drugs

Reuters
·
25 Apr